Impact of COVID-19 on multiple sclerosis care and management: Results from the European Committee for Treatment and Research in Multiple Sclerosis survey.
Coronavirus disease-19
Multiple sclerosis
access to care
disease-modifying treatment
telemedicine
Journal
Multiple sclerosis (Houndmills, Basingstoke, England)
ISSN: 1477-0970
Titre abrégé: Mult Scler
Pays: England
ID NLM: 9509185
Informations de publication
Date de publication:
01 2022
01 2022
Historique:
pubmed:
26
3
2021
medline:
25
12
2021
entrez:
25
3
2021
Statut:
ppublish
Résumé
The spread of Coronavirus disease-19 (COVID-19) poses unique challenges in the management of people with multiple sclerosis (PwMS). To collect data about the impact of COVID-19 emergency on access to care for PwMS and on MS treatment practices. Between March and July 2020, the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) promoted an online survey covering patient access to care, management of relapses and visits, disease-modifying therapy (DMT) and experience with COVID-19. Three-hundred and sixty neurologists from 52 countries (68% from Europe) completed the survey. 98% reported COVID-19-related restrictions. Telemedicine was adopted to overcome the limited access to care and was newly activated (73%) or widely implemented (17%). 70% reported changes in DMT management. Interferons and glatiramer were considered safe. Dimethyl fumarate, teriflunomide and fingolimod were considered safe except for patients developing lymphopenia. No modifications were considered for natalizumab in 64%, cladribine in 24%, anti-CD20 in 22% and alemtuzumab in 17%; 18% (for alemtuzumab and cladribine) and 43% (for anti-CD20) considered postponing treatment. The ECTRIMS survey highlighted the challenges in keeping standards of care in clinical practice. Telemedicine clearly needs to be implemented. Gathering data on DMT safety will remain crucial to inform treatment decisions.
Sections du résumé
BACKGROUND
The spread of Coronavirus disease-19 (COVID-19) poses unique challenges in the management of people with multiple sclerosis (PwMS).
OBJECTIVES
To collect data about the impact of COVID-19 emergency on access to care for PwMS and on MS treatment practices.
METHODS
Between March and July 2020, the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) promoted an online survey covering patient access to care, management of relapses and visits, disease-modifying therapy (DMT) and experience with COVID-19.
RESULTS
Three-hundred and sixty neurologists from 52 countries (68% from Europe) completed the survey. 98% reported COVID-19-related restrictions. Telemedicine was adopted to overcome the limited access to care and was newly activated (73%) or widely implemented (17%). 70% reported changes in DMT management. Interferons and glatiramer were considered safe. Dimethyl fumarate, teriflunomide and fingolimod were considered safe except for patients developing lymphopenia. No modifications were considered for natalizumab in 64%, cladribine in 24%, anti-CD20 in 22% and alemtuzumab in 17%; 18% (for alemtuzumab and cladribine) and 43% (for anti-CD20) considered postponing treatment.
CONCLUSION
The ECTRIMS survey highlighted the challenges in keeping standards of care in clinical practice. Telemedicine clearly needs to be implemented. Gathering data on DMT safety will remain crucial to inform treatment decisions.
Identifiants
pubmed: 33764197
doi: 10.1177/13524585211005339
pmc: PMC8689421
doi:
Substances chimiques
Immunosuppressive Agents
0
Fingolimod Hydrochloride
G926EC510T
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
132-138Références
Neurol Neuroimmunol Neuroinflamm. 2020 Jul 9;7(5):
pubmed: 32646885
Mult Scler. 2020 Sep;26(10):1163-1171
pubmed: 32772807
PLoS One. 2020 Oct 22;15(10):e0241103
pubmed: 33091088
Eur J Neurol. 2021 Oct;28(10):3369-3374
pubmed: 32978860
eNeurologicalSci. 2020 Dec;21:100287
pubmed: 33163634
Int J MS Care. 2020 Jul-Aug;22(4):151-157
pubmed: 32863782
N Engl J Med. 2020 Apr 30;382(18):1679-1681
pubmed: 32160451
Mult Scler. 2021 Feb;27(2):178-179
pubmed: 33325790
Neurology. 2020 May 26;94(21):903-904
pubmed: 32238505
Ann Neurol. 2021 Apr;89(4):780-789
pubmed: 33480077
Pract Neurol. 2011 Oct;11(5):283-8
pubmed: 21921003
J Neurol. 2020 Dec;267(12):3467-3475
pubmed: 32638107
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
Mult Scler. 2020 Sep;26(10):1153-1156
pubmed: 32552382
Neurology. 2020 Jun 2;94(22):949-952
pubmed: 32241953
JAMA Neurol. 2020 Sep 1;77(9):1079-1088
pubmed: 32589189
Mult Scler Relat Disord. 2020 Nov;46:102472
pubmed: 32890817
Lancet Respir Med. 2021 Feb;9(2):196-206
pubmed: 33189161
Mult Scler Relat Disord. 2020 Apr;39:102073
pubmed: 32334820
J Neurol Neurosurg Psychiatry. 2001 Jul;71(1):63-6
pubmed: 11413265